01—Abstract
Summary
Summary of the 8-K filed September 11, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. filed a Current Report on Form 8-K dated September 11, 2025, disclosing a leadership change under Item 5.02.
The Company announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss a transition period that will end no later than December 31, 2025, to ensure continuity and an orderly handover of her responsibilities. Ms. MacKay will continue in her current duties until her departure.
The filing contains no financial results, guidance, or other operating metrics. The only other item is Item 9.01, which lists the Inline XBRL cover page (Exhibit 104) for the report.
For investors, the filing is a governance update rather than a financial event. The key items to monitor are the identity of a successor for the General Counsel and Corporate Secretary roles and the completion of the transition by the December 31, 2025 outside date.
02—Key points
Key Highlights
- Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, is leaving West Pharmaceutical Services, Inc.
- The Company and Ms. MacKay have agreed to discuss a transition period ending no later than December 31, 2025.
- Ms. MacKay will continue her current duties until she leaves the Company.
- The announcement was made on September 11, 2025, and disclosed under Item 5.02 (Departure of Certain Officers).
- The filing includes no financial results, financial statements, or guidance.
- Item 9.01 lists only the Inline XBRL cover page (Exhibit 104) for the report.
03—Questions
Frequently Asked Questions
Who is leaving West Pharmaceutical Services?
Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, is leaving the Company, as announced on September 11, 2025.
When will Ms. MacKay's departure take effect?
The filing says the Company and Ms. MacKay have agreed to discuss an appropriate transition period that will end no later than December 31, 2025. Ms. MacKay will continue her current duties until she leaves.
Does this filing include any financial results or guidance?
No. The filing covers only the officer departure under Item 5.02 and lists the Inline XBRL cover page as its only exhibit under Item 9.01.
Who will take over the General Counsel and Corporate Secretary responsibilities?
The filing does not name a successor or interim replacement. It states only that the transition is intended to ensure continuity and an orderly handover of her responsibilities.
How did the Company describe Ms. MacKay's departure?
The Company thanked Ms. MacKay for her exemplary service and contributions during her tenure and wished her success in her future endeavors.
04—Continue